- Implement a proteomic platform focused on clinical applications
- Discovery of biomarkers for diagnosis, prognosis of diseases and monitor drug response
- The platform is built on state-of-the-art mass spectrometry technology
Luxembourg Clinical Proteomics
The Luxembourg Clinical Proteomics Center (LCP) Competence Center, within the Luxembourg Biomedical Research Resources (LBR2) at CRP-Santé is a shared core resource facility that aims to translate biomedical knowledge into clinical assays using state-of-the-art mass spectrophotometry techniques.
The discovery and validation of novel protein biomarkers is crucial for the early diagnosis and prognosis of many diseases, fostering a shift in medical practices towards predictive, preventive, and personalized medicine. The mission of the LCP is to develop robust, high throughput protein-based clinical assays that enable early diagnosis of disease (e.g., cancer, neurodegenerative disease, and diabetes) and prognoses for disease progression.
Activities within the LCP Center include:
- Development of methodologies for systematic quantitative analysis of proteins
- Discovery of protein biomarkers associated with cancers and infectious diseases
- Implementation of a mass spectrometry-based platform for clinical proteomics studies
The LCP Center works in close collaboration with researchers from the University of Luxembourg, the Integrated BioBank of Luxembourg (IBBL), regional and international hospitals and other types of organizations.
The Luxembourg clinical Proteomics, funded by a PEARL grant from Fonds National de la Recherche (FNR), aims at developing and implementing a proteomics platform focused on clinical applications.
This newly established biomarker research group within CRP-Santé is part of a wider effort in Luxembourg to develop projects that are at the forefront of biomedical research. This effort includes the Integrated BioBank of Luxembourg (IBBL), nearby hospitals and other disease researchers.
The discovery and validation of novel, reliable, protein biomarkers is crucial for the early diagnosis and prognosis of many diseases. Eventually it will benefits to the whole healthcare system.
The LCP is headed by Bruno Domon , PhD, who was the former Group Leader at the Institute for Molecular Systems Biology at the Swiss Federal Institute of Technology in Zurich and Director of Proteomics/Mass Spectrometry at Celera Genomics in Rockville, Maryland in the US. Dr. Domon holds concurrent positions as Head of the LBR2 Competence Center at CRP-Santé and Invited Professor at the University of Luxembourg. The results of Dr. Domon’s research are widely published in internationally recognized, peer-reviewed scientific journals.